Rare disease specialist, Alexion Pharmaceuticals� $ALXN new treatment, Strensiq, meant to cure inherited bone disorders, which costs up to $2 million a year for a patient, got clearance in the U.K. However, Britain�s health cost watchdog, the National Heath and Care Excellence, wants the company to slash the prices of the treatment. The regulator had earlier in December disapproved the treatment saying it was too expensive. The authority said that the treatment has the potential to save lives for a handful of young children and babies.